Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Target Price at $28.67

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been given an average rating of “Moderate Buy” by the five analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $28.6667.

KYTX has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Kyverna Therapeutics in a research report on Thursday, April 23rd. Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KYTX. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at $15,667,000. AIGH Capital Management LLC purchased a new stake in Kyverna Therapeutics during the fourth quarter valued at about $14,100,000. Balyasny Asset Management L.P. purchased a new stake in Kyverna Therapeutics during the fourth quarter valued at about $9,220,000. Propel Bio Management LLC purchased a new stake in Kyverna Therapeutics during the fourth quarter valued at about $6,267,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Kyverna Therapeutics during the fourth quarter valued at about $5,640,000. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Price Performance

Shares of NASDAQ:KYTX opened at $10.23 on Wednesday. The company has a market cap of $619.22 million, a P/E ratio of -2.80 and a beta of 2.05. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.11. Kyverna Therapeutics has a 52 week low of $2.06 and a 52 week high of $13.67. The business has a fifty day simple moving average of $8.93 and a 200-day simple moving average of $8.32.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. Equities research analysts forecast that Kyverna Therapeutics will post -3.18 EPS for the current year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.